½ÃÀ庸°í¼­
»óǰÄÚµå
1616701

Ç÷¾× Ç÷¼ÒÆÇ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Blood Platelets Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷¾× Ç÷¼ÒÆÇ ½ÃÀåÀº 2023³â¿¡ 56¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº ¼öÇ÷ ¼ö¿ä Áõ°¡¿Í ÇÔ²² ¸¸¼ºÁúȯ ¹× Ç÷¾× °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¸¸¼ºÁúȯ°ú Ç÷¾× °ü·Ã ÁúȯÀº ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. °í·ÉÈ­, »ýȰ½À°ü °ü·Ã °Ç°­ ¹®Á¦, ¾Ï ¹ßº´·üÀÇ ±Þ°ÝÇÑ Áõ°¡ µîÀÌ ÁÖ¿ä µµÀü ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é ¿¬°£ 1,790¸¸ ¸íÀÌ ½ÉÇ÷°ü ÁúȯÀ¸·Î »ç¸ÁÇϰí ÀÖÀ¸¸ç, ±× Áß »ó´ç¼ö°¡ Ç÷¼ÒÆÇ Ä¡·á¿Í °ü·ÃÀÌ ÀÖ´Ù°í ÇÕ´Ï´Ù.

ÇåÇ÷°ú Ç÷¼ÒÆÇ ¼öÇ÷¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀº ½ÃÀå¿¡¼­ µÎµå·¯Áø Ãß¼¼ÀÔ´Ï´Ù. ¼¼°è ÇåÇ÷ÀÇ ³¯°ú °°Àº Ä·ÆäÀÎÀº ÇåÇ÷°ú Ç÷¼ÒÆÇ ¼öÇ÷ÀÇ Á߿伺À» È¿°úÀûÀ¸·Î °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä·ÆäÀÎÀº ÀÚ¹ßÀûÀÎ ÇåÇ÷À» Àå·ÁÇÏ¿© ¼ö¼ú ¹× ¿Ü»ó Ä¡·á¸¦ Æ÷ÇÔÇÑ Çʼö Ä¡·á¿¡ ÇÊ¿äÇÑ Ç÷¼ÒÆÇ °ø±Þ·®À» Áõ°¡½Ãŵ´Ï´Ù. Àüü »ê¾÷Àº Ç÷¼ÒÆÇ À¯Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

½ÃÀåÀº Ç÷¼ÒÆÇ À¯ÇüÀ» ¾ÆÆç·¹½Ã½º À¯·¡ Ç÷¼ÒÆÇ°ú ÀüÇ÷ À¯·¡ Ç÷¼ÒÆÇÀ¸·Î ºÐ·ùÇϰí ÀÖ½À´Ï´Ù. ¾ÆÆç·¹½Ã½º À¯·¡ Ç÷¼ÒÆÇ ºÎ¹®Àº 2023³â 30¾ï ´Þ·¯ÀÇ ¸ÅÃâ·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾ÆÆç·¹½Ã½º ±â¼úÀº ±âÁ¸ÀÇ ÀüÇ÷ ÇåÇ÷º¸´Ù ÇÑ ¸íÀÇ ±âÁõÀڷκÎÅÍ ´õ ¸¹Àº Ç÷¼ÒÆÇÀ» äÃëÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ ´É·ÂÀº ¼ö¼úÀ̳ª ¾Ï Ä¡·á¿Í °°Àº ÀÀ±ÞÀÇ·á ½Ã³ª¸®¿À¿¡¼­ Ç÷¼ÒÆÇ¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä¸¦ ÃæÁ·½ÃŰ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Ç÷¼ÒÆÇÀÇ ¿ëµµ´Â Ç÷¼ÒÆÇ °¨¼ÒÁõ, Ç÷¾× Á¾¾çÇÐ, ¼ö¼ú ÀüÈÄ ÀûÀÀÁõ, Ç÷¿ìº´, Ç÷¼ÒÆÇ ±â´É Àå¾Ö µîÀ» Æ÷ÇÔÇÕ´Ï´Ù.

½ÃÀå ¹üÀ§
°³½Ã³â 2023³â
¿¹Ãø³â 2024-2032³â
°³½Ã °¡°Ý 56¾ï ´Þ·¯
¿¹»ó °¡°Ý 83¾ï ´Þ·¯
CAGR 4.2%

2023³â¿¡´Â Ç÷¼ÒÆÇ °¨¼ÒÁõ ºÎ¹®ÀÌ 44.3%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. Ç÷¼ÒÆÇ ¼ö °¨¼Ò¸¦ Ư¡À¸·Î ÇÏ´Â Ç÷¼ÒÆÇ °¨¼ÒÁõÀº ÀϹÝÀûÀ¸·Î ÀÚ°¡¸é¿ª Áúȯ, °¨¿° ¹× ƯÁ¤ ¾Ï°ú °°Àº Áúº´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇ °¨¼ÒÁõÀº ÀϹÝÀûÀ¸·Î ÀÚ°¡¸é¿ªÁúȯ, °¨¿°, ƯÁ¤ ¾Ï°ú °°Àº Áúº´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀÇ È®»êÀº Ç÷¼ÒÆÇ ¼öÇ÷ÀÇ °ü¸® ¹× Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì Ç÷¼ÒÆÇ ½ÃÀåÀº 2023³â 15¾ï ´Þ·¯ ±Ô¸ð·Î 2024-2032³â ¿¬Æò±Õ 2.8%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ¹éÇ÷º´°ú ¸²ÇÁÁ¾À» Æ÷ÇÔÇÑ Ç÷¾× ÁúȯÀÇ ¹ß»ýÀÌ µÎµå·¯Áý´Ï´Ù. ¾Ï ȯÀÚ ¹× Ç÷¾× Áúȯ ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¹× ¿¬±¸¸¦ À§ÇÑ Ç÷¼ÒÆÇ ¼ö¿äµµ Áõ°¡ÇÒ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • »ê¾÷¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯ°ú Ç÷¾× °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡
      • ¼öÇ÷ ¼ö¿äÀÇ Áõ°¡
      • ÇåÇ÷°ú Ç÷¼ÒÆÇ ¼öÇ÷¿¡ °üÇÑ ÀǽÄÀÇ Çâ»ó
      • ¿Ü°ú¼ö¼ú °Ç¼öÀÇ Áõ°¡
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ©¡¤°úÁ¦
      • °¨¿°Áõ Àü¿°ÀÇ ³ôÀº ¸®½ºÅ©
      • Ä¡·áºñÀÇ »ó½Â
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼ú »óȲ
  • »óȯ ½Ã³ª¸®¿À
  • °¡°Ý ºÐ¼®, Áö¿ªº°, 2021-2032³â
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ¾Æ¸£ÇîÆ¼³ª
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Ç÷¼ÒÆÇ À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¾ÆÆä·¹½Ã½º À¯·¡ Ç÷¼ÒÆÇ
  • ÀüÇ÷À¯·¡ Ç÷¼ÒÆÇ

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Ç÷¼ÒÆÇ °¨¼ÒÁõ
  • Ç÷¾× Á¾¾çÇÐ
  • ÁÖ¼ú±â ÀûÀÀ
  • Ç÷¿ìº´
  • Ç÷¼ÒÆÇ ±â´É Àå¾Ö
  • ±âŸ

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • American Association of Blood Banks(AABB)
  • American National Red Cross
  • America's Blood Centers
  • Blood Centers of America
  • Brazilian Red Cross
  • Canada Blood Services
  • French Red Cross
  • German Red Cross
  • Indian Red Cross Society
  • Italian Red Cross
  • Japanese Red Cross Society
  • OneBlood
  • Red Cross Society of China
  • South African Red Cross
  • Spanish Red Cross
  • The European Blood Alliance(EBA)
KSA 25.01.08

The Global Blood Platelets Market was valued at USD 5.6 billion in 2023 and is projected to grow at a CAGR of 4.2% from 2024 to 2032. This growth is primarily fueled by the rising prevalence of chronic and blood-related disorders, alongside an increasing demand for blood transfusions. Chronic and blood-related disorders are key drivers of market expansion. Contributing factors include an aging population, lifestyle-related health challenges, and a surge in cancer rates. For example, the World Health Organization reports that cardiovascular diseases account for 17.9 million deaths annually, many of which involve platelet therapies.

Growing awareness about blood donations and platelet transfusions is becoming a prominent trend in the market. Initiatives like World Blood Donor Day have effectively underscored the importance of blood and platelet donations. Such campaigns are boosting voluntary donations, thereby increasing the platelet supply for essential medical treatments, including surgeries and trauma care. The overall industry is segmented into platelet type, application, end-use, and region.

The market categorizes platelet types into apheresis-derived platelets and whole-blood-derived platelets. The apheresis-derived platelets segment led with a revenue of USD 3 billion in 2023. Apheresis technology enables the collection of a greater number of platelets from a single donor than traditional whole-blood donations. This capability is vital for addressing the high demand for platelets in urgent medical scenarios, such as surgeries and cancer treatments. Applications of blood platelets include thrombocytopenia, hemato-oncology, perioperative indications, hemophilia, platelet function disorders, and others.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$5.6 Billion
Forecast Value$8.3 Billion
CAGR4.2%

In 2023, the thrombocytopenia segment led the market with a 44.3% share. Thrombocytopenia, marked by a reduced platelet count, is commonly linked to disorders like autoimmune diseases, infections, and certain cancers. This widespread occurrence drives a robust demand for platelet transfusions in its management and treatment. North America blood platelets market accounted for USD 1.5 billion in 2023, with projections of a 2.8% CAGR from 2024 to 2032. The region sees a notable incidence of blood disorders, including leukemia and lymphoma.As the number of cancer patients and individuals with blood disorders rises, so does the demand for blood platelets for both treatments and research.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic and blood-related disorders
      • 3.2.1.2 Growing demand for blood transfusions
      • 3.2.1.3 Rise in awareness regarding blood donations and platelets transfusions
      • 3.2.1.4 Rising number of surgical procedures
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High risk of transmissions of infections
      • 3.2.2.2 High cost of the treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Reimbursement scenario
  • 3.7 Pricing analysis, by region, 2021-2032
    • 3.7.1 North America
      • 3.7.1.1 U.S.
      • 3.7.1.2 Canada
    • 3.7.2 Europe
      • 3.7.2.1 Germany
      • 3.7.2.2 UK
      • 3.7.2.3 France
      • 3.7.2.4 Spain
      • 3.7.2.5 Italy
    • 3.7.3 Asia Pacific
      • 3.7.3.1 China
      • 3.7.3.2 Japan
      • 3.7.3.3 India
      • 3.7.3.4 Australia
      • 3.7.3.5 South Korea
    • 3.7.4 Latin America
      • 3.7.4.1 Brazil
      • 3.7.4.2 Mexico
      • 3.7.4.3 Argentina
    • 3.7.5 MEA
      • 3.7.5.1 South Africa
      • 3.7.5.2 Saudi Arabia
      • 3.7.5.3 UAE
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Future market trends
  • 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Competitive positioning matrix
  • 4.3 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Platelet type, 2021 - 2032 ($ Mn & Units)

  • 5.1 Key trends
  • 5.2 Apheresis derived platelets
  • 5.3 Whole blood derived platelet

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Thrombocytopenia
  • 6.3 Hemato-oncology
  • 6.4 Perioperative indications
  • 6.5 Hemophilia
  • 6.6 Platelet function disorders
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 American Association of Blood Banks (AABB)
  • 9.2 American National Red Cross
  • 9.3 America's Blood Centers
  • 9.4 Blood Centers of America
  • 9.5 Brazilian Red Cross
  • 9.6 Canada Blood Services
  • 9.7 French Red Cross
  • 9.8 German Red Cross
  • 9.9 Indian Red Cross Society
  • 9.10 Italian Red Cross
  • 9.11 Japanese Red Cross Society
  • 9.12 OneBlood
  • 9.13 Red Cross Society of China
  • 9.14 South African Red Cross
  • 9.15 Spanish Red Cross
  • 9.16 The European Blood Alliance (EBA)
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦